HAM PROTOKOLÜ

Kaynaklar:

1- Büchner T, Hiddemann W, Berdel WE, et al.: 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003, 21: 4496–4504.

2- Buchner, T. W. E. Berdel, C. Schoch, et al. 2006. "Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia." J Clin Oncol 24(16):2480-2489. 

3- Hiddemann, W., H. Kreutzmann, K. Straif, et al. 1987. "High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia." Blood 69(3):744-749. 

4- Lowenberg, B., S. Suciu, E. Archimbaud, et al. 1998. "Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group." J Clin Oncol 16(3):872-881.

5- Arlin, Z. D. C. Case, Jr., J. Moore, et al. 1990. "Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group." Leukemia 4(3):177-183. 

6- Hiddemann, W. C. Aul, G. Maschmeyer, et al. 1993. "High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison." Leuk Lymphoma 10 Suppl:133-137.